Clinical Trials on Non-Cystic Fibrosis Bronchiectasis in Switzerland

Total 48 results

Zambon SpA

Completed

Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I) (PROMIS-I)

Non Cystic Fibrosis Bronchiectasis

Australia, Greece, Israel, Italy, Portugal, Belgium, Germany, Netherlands, New Zealand, Spain, Switzerland, United Kingdom
University Hospital Inselspital, Berne
Centre Hospitalier Universitaire Vaudois; Kantonsspital Aarau; University Children... and other collaborators

Recruiting

Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis (SCILD)

Confirmed Diagnosis of Cystic Fibrosis

Switzerland
University of Zurich
University of Manchester

Completed

Developing and Validating a Patient-reported Outcome Instrument to Monitor Symptom Management in Pulmonary Exacerbation in CF

Cystic Fibrosis

Switzerland
University of Zurich

Completed

Exercise and Oscillatory Positive Expiratory Pressure Therapy in Cystic Fibrosis

Cystic Fibrosis

Switzerland
University Hospital Inselspital, Berne

Active, not recruiting

Prospective Surveillance of Lung Development During Childhood, Adolescence and Adulthood in Healthy and Patients With Cystic Fibrosis (Prospective)

Healthy | Cystic Fibrosis

Switzerland
University of Zurich

Completed

Breath Analysis in in Adults With Cystic Fibrosis (CF)

Cystic Fibrosis

Switzerland
University of Zurich

Completed

Effect of a Nursing Program for Patients With Cystic Fibrosis on Disease Management

Cystic Fibrosis

Switzerland
University Hospital Inselspital, Berne
Lindenhofspital

Completed

Prediction of Survival in Children With Cystic Fibrosis Using the Multiple-breath Washout

Death | Cystic Fibrosis | Lung Transplantation

Switzerland
Société des Produits Nestlé (SPN)

Completed

Lipid Formulation to Increase the Bioavailability of Fatty Acids in Cystic Fibrosis (CF) Patients

Cystic Fibrosis

Switzerland
Christoph Saner
University Hospital Inselspital, Berne

Completed

Glucose Tolerance in Children With Cystic Fibrosis (GluTolCF)

Glucose Intolerance | Cystic Fibrosis

Switzerland
Cantonal Hospital of St. Gallen
University Hospital Inselspital, Berne; Swiss Federal Institute of Technology

Unknown

Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Diet Supplementation in Pediatric Cystic Fibrosis (MoHuM-1)

Cystic Fibrosis | Microbiota | Pulmonary Inflammation

Switzerland
Julius-Maximilians University
Hannover Medical School; Goethe University; Triemli Hospital; Mukoviszidose eV... and other collaborators

Completed

Effects of a 6-Months Physical Conditioning Program in Patients With Cystic Fibrosis

Cystic Fibrosis

Germany, Switzerland
Novartis Pharmaceuticals

Completed

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years (EARLY)

Treatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients

Egypt, Greece, Hungary, Russian Federation, Canada, Germany, France, Italy, Switzerland, Romania
Insel Gruppe AG, University Hospital Bern
Cystic Fibrosis Foundation; European Cystic Fibrosis Society

Recruiting

COVID-19 Antibody Responses In Cystic Fibrosis (CAR-CF)

Cystic Fibrosis

Switzerland
University of Bern

Completed

Comparison of ER:YAG Laser, CO2 Laser and Scalpel Excision of Fibrous Hyperplasia on the Buccal Mucosa

Fibrous Hyperplasia on Oral Mucosa

Switzerland
Novartis Pharmaceuticals

Completed

Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)

Cystic Fibrosis

Spain, Germany, Switzerland, United Kingdom, Ireland
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis

Cystic Fibrosis

United Kingdom, France, Germany, Australia, Switzerland, Ireland, Belgium, Denmark, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

Cystic Fibrosis

Canada, France, Germany, United Kingdom, Israel, Australia, Spain, Netherlands, Denmark, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

Cystic Fibrosis

Canada, France, United Kingdom, Israel, Australia, Spain, Germany, Netherlands, Denmark, Switzerland
Vertex Pharmaceuticals Incorporated

Enrolling by invitation

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

Cystic Fibrosis

United States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Cystic Fibrosis

United States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
Bambino Gesù Hospital and Research Institute
Radboud University Medical Center; University of Exeter; Consorzio per Valutazioni...

Recruiting

A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection (cASPerCF)

Cystic Fibrosis | Aspergillosis

Ireland, Spain, Netherlands, France, United Kingdom, Czechia, Germany, Greece, Italy, Portugal, Switzerland
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Switzerland, Italy, Czechia, Portugal, Austria, Hungary, Norway, Poland
University of Oxford
Assistance Publique - Hôpitaux de Paris; University of Nottingham; Novartis; Pf... and other collaborators

Active, not recruiting

LITMUS Imaging Study

NAFLD | Fibrosis, Liver | NASH - Nonalcoholic Steatohepatitis | NASH | Steatosis of Liver

United Kingdom, Finland, Sweden, Spain, Greece, United States, Switzerland, Italy, France, Germany
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Italy, Czechia, Switzerland, Portugal, Austria, Hungary, Norway, Poland
Ali Aminian

Not yet recruiting

Fibrosis Lessens After Metabolic Surgery (FLAMES)

Obesity | Liver Fibrosis | Non-Alcoholic Fatty Liver Disease | Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) | Metabolic Dysfunction-Associated Steatohepatitis (MASH)

United States, Sweden, Ireland, Finland, United Kingdom, Spain, Switzerland, Brazil, Canada, Italy, Kuwait, India, Mexico
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

Cystic Fibrosis

United States, Germany, United Kingdom, Canada, Australia, Switzerland, France, Ireland, Belgium, Denmark, Poland
Vertex Pharmaceuticals Incorporated

Terminated

A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Australia, Israel, United Kingdom, Germany, Canada, Denmark, Poland, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Spain, Ireland, Australia, Israel, United Kingdom, Germany, Switzerland, Canada, Denmark, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

Cystic Fibrosis

United States, United Kingdom, Germany, Spain, Switzerland, Canada, Netherlands, Italy, Ireland, Sweden, France, Denmark
Boehringer Ingelheim

Completed

Tiotropium Bromide in Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Ireland, Israel, Italy, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, Switzerland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

Cystic Fibrosis

United States, Australia, Canada, Germany, Switzerland, Israel, Netherlands, Belgium, Italy, United Kingdom, France
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Israel, Australia, United Kingdom, Germany, Canada, Denmark, Poland, Switzerland
Wuerzburg University Hospital

Completed

Effects of a Partially Supervised Conditioning Program in CF (ACTIVATE-CF)

Cystic Fibrosis

United States, Austria, Canada, France, Germany, Netherlands, Switzerland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Cystic Fibrosis

United States, United Kingdom, Belgium, Netherlands, France, Denmark, Israel, New Zealand, Australia, Ireland, Sweden, Canada, Germany, Poland, Switzerland, Italy, Austria, Hungary, Greece, Norway
Vertex Pharmaceuticals Incorporated

Active, not recruiting

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Cystic Fibrosis

United States, Spain, United Kingdom, Belgium, Netherlands, Denmark, Israel, New Zealand, France, Australia, Ireland, Germany, Sweden, Canada, Czechia, Switzerland, Portugal, Italy, Austria, Hungary, Norway, Poland, Greece
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Cystic Fibrosis

United States, Australia, Canada, France, United Kingdom, Germany, Spain, Switzerland, Belgium, Israel, Netherlands, Denmark, Italy, Austria, Ireland, Sweden
Gilead Sciences
Covance; ClinPhone, Inc.; Chiltern International Inc.

Completed

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

Cystic Fibrosis

Belgium, France, Germany, Italy, Netherlands, Spain, United States, Ireland, United Kingdom, Portugal, Austria, Denmark, Switzerland
University Hospital, Basel, Switzerland
Swiss National Science Foundation

Recruiting

MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease

Liver Failure | Acute-On-Chronic Liver Failure | Liver Disease | Cirrhosis of the Liver

Switzerland, United Kingdom
Tobira Therapeutics, Inc.

Terminated

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) (AURORA)

Nonalcoholic Steatohepatitis

United States, Spain, Australia, Belgium, Israel, Canada, Puerto Rico, Italy, Germany, France, New Zealand, Taiwan, Poland, United Kingdom, Brazil, Austria, Singapore, Portugal, Chile, Greece, Hong Kong, Hungary, Latvia, Mexico, Norway, R... and more
Genfit

Terminated

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) (RESOLVE-IT)

Nonalcoholic Steatohepatitis (NASH) With Fibrosis

United States, Belgium, Germany, France, Canada, Netherlands, Italy, Switzerland, Finland, Puerto Rico, United Kingdom, Denmark, Spain, Australia, Czechia, Sweden, Romania, Argentina, Portugal, Turkey, Mexico, Colombia, South Africa, ... and more
Cellestia Biotech AG

Terminated

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Breast Cancer | Adenoid Cystic Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Osteosarcoma | Non-hodgkin Lymphoma | Glomus Tumor, Malignant | T-ALL

United States, Spain, Korea, Republic of, Germany, France, Switzerland
Bristol-Myers Squibb

Terminated

Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States, Germany, Taiwan, United Kingdom, Spain, Argentina, Brazil, France, Israel, Italy, Japan, Korea, Republic of, Belgium, Canada, Puerto Rico, Switzerland
Newcastle University
Assistance Publique - Hôpitaux de Paris; Medical University of Vienna; University... and other collaborators

Recruiting

The European NAFLD Registry

Cardiovascular Diseases | Hypertension | Obesity | Hepatocellular Carcinoma | Type 2 Diabetes | NAFLD | Fibrosis, Liver | NASH - Nonalcoholic Steatohepatitis | Dyslipidaemia | NASH | Steatosis of Liver | Other Associated Comorbidities

Netherlands, Germany, United Kingdom, Finland, Belgium, Greece, Italy, Sweden, Portugal, Spain, France, Switzerland
Jonel Trebicka

Completed

Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study (PREDICT)

Liver Cirrhosis With Acute Decompensation

Spain, Germany, Denmark, Austria, Belgium, United Kingdom, Netherlands, Switzerland, Hungary, Italy, France, Portugal, Slovakia, Turkey
European Foundation for Study of Chronic Liver...

Recruiting

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs (CHANCE)

Liver Diseases | Liver Cirrhosis | Acute-On-Chronic Liver Failure | Liver Transplant; Complications

Spain, United States, Germany, Belgium, United Kingdom, Japan, Mexico, Taiwan, Korea, Republic of, Canada, France, Australia, Italy, Argentina, Austria, Brazil, Colombia, Czechia, Hong Kong, India, Netherlands, New Zealand, Poland, Po... and more
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Study of Kidney Tumors in Younger Patients

Renal Cell Carcinoma | Wilms Tumor | Clear Cell Sarcoma of the Kidney | Papillary Renal Cell Carcinoma | Kidney Medullary Carcinoma | Diffuse Hyperplastic Perilobar Nephroblastomatosis | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Renal Cell Carcinoma Associated With Xp11.2 Translocations... and other conditions

United States, Canada, Puerto Rico, Australia, New Zealand, Israel, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Chordoma | Rhabdomyosarcoma | Recurrent Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Adult Rhabdomyosarcoma | Metastatic Childhood Soft Tissue Sarcoma | Untreated Childhood Rhabdomyosarcoma | Stage I Adult Soft Tissue Sarcoma AJCC v7 and other conditions

United States, Netherlands, Canada, Australia, New Zealand, Puerto Rico, Switzerland

Clinical Trials on Non-Cystic Fibrosis Bronchiectasis in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations